<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662996</url>
  </required_header>
  <id_info>
    <org_study_id>DR200300 _MiR_CPMRC</org_study_id>
    <nct_id>NCT04662996</nct_id>
  </id_info>
  <brief_title>Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs</brief_title>
  <acronym>MiR_CPMRC</acronym>
  <official_title>Search for Predictive Factors of Resistance to Treatment for Metastatic Castration-resistant Prostate Cancer by Studying the Expression of microRNAs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several drugs are available for metastatic castration resistant prostate cancer such as&#xD;
      chemotherapy (docetaxel, cabazitaxel) and novel hormonal agents (abiraterone, enzalutamide),&#xD;
      in France. The oncologist has to choose between those two type of treatment, without any&#xD;
      biological predictor of efficacy for his patient. It is always difficult to choose knowing&#xD;
      that 30 to 50% of patients won't benefit from the treatment chosen. It shows why resistant&#xD;
      mechanisms to treatment need to be elucidated. MicroRNA (miR) are short RNA, implicated in&#xD;
      messenger ribonucleic acid (mRNA) regulation. Evidence is emerging that miR is implicated in&#xD;
      prostate cancer response to treatment. It would be interesting to determine if a miR profile&#xD;
      can predict treatment response to chemotherapy and/or to novel hormonal agents.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several drugs are available for metastatic castration resistant prostate cancer such as&#xD;
      chemotherapy (docetaxel, cabazitaxel) and novel hormonal agents (abiraterone, enzalutamide),&#xD;
      in France. The oncologist has to choose between those two type of treatment, without any&#xD;
      biological predictor of efficacy for his patient. It is always difficult to choose knowing&#xD;
      that 30 to 50% of patients won't benefit from the treatment chosen. It shows why resistant&#xD;
      mechanisms to treatment need to be elucidated. MicroRNA (miR) are short RNA, implicated in&#xD;
      messenger ribonucleic acid (mRNA) regulation. Evidence is emerging that miR is implicated in&#xD;
      prostate cancer response to treatment. It would be interesting to determine if a miR profile&#xD;
      can predict treatment response to chemotherapy and/or to novel hormonal agents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention: blood sample at inclusion. primary purpose: to better understand resistance mechanisms to prostate cancer treatment.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>miRNA and chemotherapy</measure>
    <time_frame>30 months</time_frame>
    <description>miRNA expression profile predicting resistance to chemotherapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>miRNA and novel hormonal agent (NHA)</measure>
    <time_frame>30 months</time_frame>
    <description>miRNA expression profile predicting resistance to novel hormonal agents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>miRNA and progression free survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>correlation between miRNA profile and progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miRNA and overall survival (OS)</measure>
    <time_frame>30 months</time_frame>
    <description>correlation between miRNA profile and overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miRNA in tissue sample</measure>
    <time_frame>30 months</time_frame>
    <description>comparison between miRNA expression in serum and in tumoral tissue</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Resistance, Disease</condition>
  <condition>MicroRNAs</condition>
  <arm_group>
    <arm_group_label>1- Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention : one blood sample is done before beginning chemotherapy as a first treatment line for a metastatic castration resistant prostate cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2- Novel Hormonal Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention : one blood sample is done before beginning a novel hormonal agent (abiraterone, enzalutamide) as a first treatment line for a metastatic castration resistant prostate cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>one blood sample is done before beginning a first treatment line for a metastatic castration resistant prostate cancer</description>
    <arm_group_label>1- Chemotherapy</arm_group_label>
    <arm_group_label>2- Novel Hormonal Agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  prostate adenocarcinoma&#xD;
&#xD;
          -  metastatic disease, proven (CT or bone scintigraphy or MRI or positron emission&#xD;
             tomography(PET)-CT or X ray)&#xD;
&#xD;
          -  castration resistance, proven with biology or radiologic progression&#xD;
&#xD;
          -  affiliated to a french social security regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other cancer within five years&#xD;
&#xD;
          -  any judiciary protection measure&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>prostate cancer only concerns male people</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mathilde cancel, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>ONCOLOGUE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>mathilde cancel, md</last_name>
    <phone>md</phone>
    <email>m.cancel@chu-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CANCEL</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol. 2015 Jan;67(1):33-41. doi: 10.1016/j.eururo.2014.07.035. Epub 2014 Aug 14.</citation>
    <PMID>25129854</PMID>
  </reference>
  <reference>
    <citation>Razdan A, de Souza P, Roberts TL. Role of MicroRNAs in Treatment Response in Prostate Cancer. Curr Cancer Drug Targets. 2018;18(10):929-944. doi: 10.2174/1568009618666180315160125. Review.</citation>
    <PMID>29644941</PMID>
  </reference>
  <reference>
    <citation>Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ, Horvath LG. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer. 2014 May 13;110(10):2462-71. doi: 10.1038/bjc.2014.181. Epub 2014 Apr 8.</citation>
    <PMID>24714754</PMID>
  </reference>
  <reference>
    <citation>Zhang G, Tian X, Li Y, Wang Z, Li X, Zhu C. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1. Biomed Pharmacother. 2018 Jan;97:736-744. doi: 10.1016/j.biopha.2017.10.163. Epub 2017 Nov 6.</citation>
    <PMID>29102917</PMID>
  </reference>
  <reference>
    <citation>Fletcher CE, Sulpice E, Combe S, Shibakawa A, Leach DA, Hamilton MP, Chrysostomou SL, Sharp A, Welti J, Yuan W, Dart DA, Knight E, Ning J, Francis JC, Kounatidou EE, Gaughan L, Swain A, Lupold SE, de Bono JS, McGuire SE, Gidrol X, Bevan CL. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene. 2019 Jul;38(28):5700-5724. doi: 10.1038/s41388-019-0823-5. Epub 2019 May 1.</citation>
    <PMID>31043708</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Disease Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

